

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 300 River Place Suite 5900 Detroit, MI 48207 (313) 393-8100 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 8/8/16, 8/9/16, 8/10/16, 8/11/16, 8/12/16, 8/16/16, 8/19/16
	FEI NUMBER 3007181436

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Anthony S. Kantzavelos, Pharm.D (Owner)

FIRM NAME Rx Compounding Inc.	STREET ADDRESS 1101 E. 86th St.
----------------------------------	------------------------------------

CITY, STATE AND ZIP CODE Indianapolis, IN 46240	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile Drug Products
--	--

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

OBSERVATION 1
Equipment, materials, and/or supplies are not adequately disinfected prior to entering the aseptic processing areas.

Specifically,


While loading the items into the pass-through chamber during the aseptic compounding of Vancomycin 25mg/ml prescription number (b)(4), (b)(6) and Tobramycin 14mg/ml prescription number (b)(4), (b)(6) the operator was observed spraying (b)(4) sterile (b)(4) onto the equipment/materials located in the (b)(4). However, the sterile (b)(4) did not make contact with all of the equipment and material surfaces prior to being being placed in the (b)(4) (b)(4) transfer chamber.

OBSERVATION 2
Personnel were observed performing aseptic manipulations that blocked the movement of first pass air around an open unit, whether before or after it is filled with sterile product.

Specifically,

During the aseptic compounding of Vancomycin 25mg/ml prescription number (b)(4), (b)(6) and Tobramycin 14mg/ml prescription number (b)(4), (b)(6) the operator was observed passing their hands over the open sterile ophthalmic bottles.

OBSERVATION 3
Personnel engaged in aseptic processing were observed wearing non-sterile gloves.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Robert M. Barbosa (Investigator)	DATE ISSUED 09/16/2016
--------------------------	--	--	---------------------------

Handwritten: 9/16/16

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER

300 River Place Suite 5900
Detroit, MI 48207
(313) 393-8100

DATE(S) OF INSPECTION

8/8/16, 8/9/16, 8/10/16, 8/11/16, 8/12/16,
8/16/16, 8/19/16

FEI NUMBER

3007181436

Industry Information: www.fda.gov/oc/industry

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED

TO: Anthony S. Kantzavelos, Pharm.D (Owner)

FIRM NAME

Rx Compounding Inc.

STREET ADDRESS

1101 E. 86th St.

CITY, STATE AND ZIP CODE

Indianapolis, IN 46240

TYPE OF ESTABLISHMENT INSPECTED

Producer of Sterile Drug Products

Specifically,

1) The gloves (b)(4) used during the aseptic compounding of Vancomycin 25mg/ml prescription number (b)(4), (b)(6) and Tobramycin 14mg/ml prescription number (b)(4), (b)(6) are non-sterile nitrile gloves which are replaced (b)(4)

2) The non-sterile nitrile gloves which are changed out (b)(4) are not sanitized with sterile (b)(4) until after they are exposed to the interior ISO 5 environment. Additionally, during the aseptic compounding of Vancomycin 25mg/ml prescription number (b)(4), (b)(6) and Tobramycin 14mg/ml prescription number (b)(4), (b)(6) the non-sterile nitrile gloves the operator was using were not form fitting with visible creases and folds in which the non-sterile glove surfaces did not make contact with the sterile (b)(4)

OBSERVATION 4

The ISO 5 classified area is located within a non-classified room.

Specifically,

The environment of the curtained anteroom surrounding the (b)(4) where all sterile prescriptions are filled is not classified nor was the HEPA filter located in this anteroom certified during your routine (b)(4) certifications performed on 1/26/16 and 7/26/16. Additionally, the HEPA filter located in the (b)(4) (b)(4) of the anteroom is partially covered by the (b)(4)

OBSERVATION 5

Chemical sanitizing agents are not used in your facilities cleanrooms.

Specifically,

The curtained anteroom floor, walls, and surfaces, in which the ISO 5 (b)(4) is located, is currently sanitized using a (b)(4) only. No sanitizing chemical agents are used during the sanitization of this room.

SEE
REVERSE
OF THIS
PAGE

EMPLOYEE(S) SIGNATURE



EMPLOYEE(S) NAME AND TITLE (Print or Type)

Robert M. Barbosa (Investigator)

DATE ISSUED

09/16/2016

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 300 River Place Suite 5900 Detroit, MI 48207 (313) 393-8100 Industry Information: www.fda.gov/oc/industry		DATE(S) OF INSPECTION 8/8/16, 8/9/16, 8/10/16, 8/11/16, 8/12/16, 8/16/16, 8/19/16
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Anthony S. Kantzavelos, Pharm.D (Owner)		FEI NUMBER 3007181436
FIRM NAME Rx Compounding Inc.	STREET ADDRESS 1101 E. 86th St.	
CITY, STATE AND ZIP CODE Indianapolis, IN 46240	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile Drug Products	

OBSERVATION 6

The environmental monitoring is performed is not representative of aseptic conditions.

Specifically,

- 1) The agar plates used for performing the (b)(4) passive viable air testing are incubated at (b)(4) (b)(4) prior to reading. Due to the excessive incubation time, the agar plates incubated on 7/15/16 were observed on (b)(4) to be completely dessicated and disintegrating. Also this lot of agar plates, lot no. (b)(4) expired on 6/3/15.
- 2) The test media used with the (b)(4) for performing the (b)(4) fingertip monitoring does not contain any sanitant neutralizing ingredients. Additionally, the (b)(4) incubated on 7/15/16 were observed on (b)(4) to be completely dessicated and disintegrating.

OBSERVATION 7

The certification of ISO 5 classified area is not representative of its condition of use.


Specifically,

The unidirectional airflow studies performed during the certification of the (b)(4) on 1/26/16 and 7/26/16 did not include studies under dynamic conditions.

OBSERVATION 8

Beta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Robert M. Barbosa (Investigator)	DATE ISSUED 09/16/2016
--------------------------	--	--	---------------------------

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 300 River Place Suite 5900 Detroit, MI 48207 (313) 393-8100 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 8/8/16, 8/9/16, 8/10/16, 8/11/16, 8/12/16, 8/16/16, 8/19/16
	FEI NUMBER 3007181436

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Anthony S. Kantzavelos, Pharm.D (Owner)


FIRM NAME Rx Compounding Inc.	STREET ADDRESS 1101 E. 86th St.
----------------------------------	------------------------------------

CITY, STATE AND ZIP CODE Indianapolis, IN 46240	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile Drug Products
--	--

On 7/20/16 Ceftriaxone 50mg/ml prescription no. (b)(4), (b)(6) was filled in your (b)(4) used for filling sterile prescriptions. The (b)(4) was subsequently re-sanitized with (b)(4) and subsequently used to fill Chlorhexidine 0.02% prescription no. (b)(4), (b)(6) on the same day.

Similarly, on 7/15/16 Amoxicillin 52.5mg/ml prescription no. (b)(4), (b)(6) was filled in your non-sterile compounding (b)(4) hood. Subsequently on 7/15/16 Enalapril 5mg/ml prescription no. (b)(4), (b)(6) was filled in this same (b)(4) hood. There was no documented cleaning of the non-sterile (b)(4) hood between the filling of these prescriptions.

Amendment 1.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Robert M. Barbosa (Investigator)	DATE ISSUED 09/16/2016
--------------------------	--	--	-------------------------------

RMB 9/16/16